DMRA
Damora Therapeutics, Inc.
NASDAQ: DMRA · HEALTHCARE · BIOTECHNOLOGY
$23.09
-5.83% today
Updated 2026-06-05
Market cap
$1.26B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.68
Dividend yield
—
52W range
$2 – $38
Volume
0.3M
WallStSmart proprietary scores
26
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C8.0
Quality
A3.0
Profitability
D5.0
Valuation
C+2/9
Piotroski F-Score
Weak
3.0
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →199 stocks currently score above 75
Price targets
Analyst target
$43.14
+86.83%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.00x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-20.60M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-61.62M | $-38.35M | $-21.44M | $-209.84M | $-27.78M |
| EPS | — | — | — | — | $-2.68 |
| Free cash flow | $-43.13M | $-36.91M | $-18.62M | $-6.73M | $-20.60M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Damora Therapeutics, Inc. trades at $23.09. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 2.98, it sits in the grey zone.
Frequently asked questions
What is Damora Therapeutics, Inc.'s stock price?
Damora Therapeutics, Inc. (DMRA) trades at $23.09.
Is Damora Therapeutics, Inc. overvalued?
Damora Therapeutics, Inc. carries a Smart Value Score of 26/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Damora Therapeutics, Inc. (DMRA)?
The 12-month analyst consensus target is $43.14, about 86.8% above the current $23.09. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Damora Therapeutics, Inc.'s Altman Z-Score is 2.98, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-89.50%
Beta1.48
50D MA$24.70
200D MA$19.87
Shares out0.06B
Float0.04B
Short ratio—
Avg volume0.3M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—